Oramed Pharmaceuticals (ORMP) has restructured its Scilex notes by entering into a Warrant Agreement with Scilex Holding Company. Oramed deferred an amortization payment and received a new warrant to purchase 100,000 shares of Scilex common stock at $20 per share. This deal includes various protections for Oramed, strengthening its exposure and risk profile regarding its investment in Scilex.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Oramed Pharmaceuticals Restructures Scilex Notes via Warrant Deal
Oramed Pharmaceuticals (ORMP) has restructured its Scilex notes by entering into a Warrant Agreement with Scilex Holding Company. Oramed deferred an amortization payment and received a new warrant to purchase 100,000 shares of Scilex common stock at $20 per share. This deal includes various protections for Oramed, strengthening its exposure and risk profile regarding its investment in Scilex.